Condition: Rheumatoid Arthritis · Sponsor: Lifordi Immunotherapeutics, Inc.
This is a double-blind, randomized, placebo- and active-controlled study investigating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous (SC) doses of LFD-200. The study design includes: a single ascending dose (SAD) study in up to 66 adult healthy participants (HPs) to investigate the effects of a single SC dose, with a 30-day follow-up; a multiple ascending dose (MAD) study in up to 40 HPs to assess up to 4 weekly SC doses, with a 30-day follow-up after the last dose; and a MAD study in up to 70 participants with moderate to severe rheumatoid arthritis (RA) to evaluate up to 13 weekly SC doses, with a 30-day follow-up after the last dose.
This description comes directly from the study's public registry record.
Matthew McClure, MD · +14158107700 · mmcclure@lifordi.com
Always discuss trial participation with your own doctor first.
| Nucleus Network | Melbourne, Australia | Active Not Recruiting |
| Arensia Exploratory Medicine LLC | Tbilisi, Georgia | Recruiting |
| Clinical Republican Hospital "Timofei Mosneaga", ARENSIA E.M. | Chisinau, Moldova | Recruiting |
| MICS Centrum Medyczne Torun - MICS - PPDS | Torun, Poland | Not Yet Recruiting |
| Centrum Medyczne Reuma Park | Warsaw, Poland | Not Yet Recruiting |
| "ARENSIA EXPLORATORY MEDICINE" LIMITED LIABILITY COMPANY, Medical Center, Department of Clinical Trials | Kyiv, Ukraine | Recruiting |
| Medical Clinical Investigational Center "Medical Center Health Clinic", LLC | Vinnytsia, Ukraine | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07207954